Companies in #Metastatic Colorectal Cancer
Found 3 companies operating in this sector.
Lyell Immunopharma is a South San Francisco-based clinical-stage cell therapy company developing next-generation CAR T-cell product candidates for hematologic malignancies and solid tumors. Its lead asset, rondecabtagene autoleucel (ronde-cel), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in the pivotal PiNACLE trial in third-line-or-later large B-cell lymphoma and in the Phase 3 PiNACLE-H2H head-to-head study in the second-line setting, with updated data across more than 80 patients reported ahead of ASH 2026. A second programme, LYL273, is a GCC-targeted CAR T enhanced with CD19 CAR expression and controlled cytokine release in Phase 1/2 for refractory metastatic colorectal cancer. The company's LyFE Manufacturing Center is designed to support registrational and commercial supply, and its platform work spans c-Jun overexpression, NR4A3 knockout, Epi-R and CD62L-positive enrichment to resist T-cell exhaustion. Lyell was incorporated in 2018, listed on Nasdaq in June 2021, and is led by President and Chief Executive Officer Lynn Seely, with founder Richard Klausner as Executive Chairman.
PDS Biotechnology is a clinical-stage immunotherapy company developing targeted cancer treatments built on the Versamune platform, a T-cell activating technology evaluated in HPV16-positive cancers, and PDS0301, an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to remodel the tumor microenvironment. Following an August 2026 strategic refocus, the company prioritized PDS0301 as its lead program in metastatic colorectal cancer (randomized Phase 2b planned) and is pursuing a partnership strategy for the Versamune/PDS0101 program. PDS0301 has been clinically evaluated across multiple solid tumors, including mCRC, prostate cancer, and Kaposi sarcoma.
Propanc Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of proenzyme-based oncology therapeutics designed to suppress tumor growth and metastasis by targeting and modulating the tumor microenvironment. Lead candidate PRP is being advanced in metastatic colorectal and pancreatic cancers. The company is pursuing an OPAL (Opposite-Pole) technology platform based on the proenzyme theory of cancer.